-
1 week ago | 
biopharminternational.com | Susan Haigney |Patrick Lavery
In BioPharm International®’s continuing conversation with Ram Aiyar, PhD, of Korro Bio, the company’s CEO and president discusses the work Korro has been doing on RNA editing for a wide range of targets, and how that research and knowledge can be brought to a wider audience of potential patients with the assistance of a major player in the biopharmaceutical industry. “That's where pharma companies really come into the picture, where it's like they are more interested.
-
1 week ago | 
biopharminternational.com | Susan Haigney |Patrick Lavery
As the Biotechnology Innovation Organization (BIO) International Convention meets in Boston from June 16–19, 2025, BioPharm International® caught up with Ram Aiyar, PhD, CEO and president of Cambridge, Mass.-based Korro Bio. In the interview, Aiyar explains the broader implications of Korro’s OPERA platform, short for “Oligonucleotide Promoted Editing of RNA.” Increased precision, he said, is the key to addressing a broader range of diseases.
-
3 weeks ago | 
biopharminternational.com | Patrick Lavery
PCI Pharma Services, headquartered in Philadelphia, is providing updates on its new purpose-built facility for large-scale sterile fill/finish operations at its Bedford, NH campus, which company representatives will be on hand to discuss with attendees at the Biotechnology Innovation Organization (BIO) International Convention, to be held June 16–19, 2025 in Boston (1). The 50,000-square-foot facility is expected to approach full-scale good manufacturing practice (GMP) production in summer 2025.
-
3 weeks ago | 
biopharminternational.com | Patrick Lavery
June 5, 2025BioPharm InternationalBioPharm International June 2025Pages: 28–30Quality, stability, sustainability, and the increased and thoughtful integration of artificial intelligence are foremost in the minds of those on the leading edge of testing trends. Drug substance testing is a critical component of the biopharmaceutical analysis process, carrying with it inherent benchmarks of safety and efficacy that must be met.
-
3 weeks ago | 
biopharminternational.com | Patrick Lavery
TriLink Biotechnologies, a San Diego-headquartered company that is part of Maravai LifeSciences, has signed a non-exclusive license and supply agreement with Belgium-based Quantoom Biosciences, under the terms of which Quantoom will gain access to TriLink’s messenger RNA (mRNA) capping technology, known as CleanCap (1).
-
3 weeks ago | 
biopharminternational.com | Patrick Lavery
As part of BioPharm International®’s coverage of the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, held in New Orleans from May 13–17, 2025, Regeneron Senior Principal Scientist Nicholas Giovannone discussed the oral presentation he gave at the meeting, “Successful AAV Vector Re-Administration via Two Distinct B Cell Immunomodulation Strategies in Non-Human Primates.” This novel approach is not an entirely new concept, Giovannone explained, but the Regeneron team’s work...
-
1 month ago | 
biopharminternational.com | Patrick Lavery
Following the AAPS National Biotechnology Conference 2025 (AAPS Bio), BioPharm International® caught up with Austin Daniels, PhD, an application scientist for Yokogawa Fluid Imaging Technologies, who presented a poster at the event, “Using Flow Imaging Microscopy to Meet Particulate Matter Standards for Biotherapeutics.” Flow imaging microscopy is effective in this application, according to Daniels, because imaging-based methods have been generally shown to be more sensitive to translucent...
-
1 month ago | 
biopharminternational.com | Patrick Lavery
At the AAPS National Biotechnology Conference 2025 (AAPS Bio), which was held in Boston from May 4–7, 2025, Jerry Chapman, principal, Quality Data & Analytics for Redica Systems, delivered an oral presentation entitled “Using Artificial Intelligence to Evaluate Potential Clinical Study Sites.” In an interview with BioPharm International® following that session, Chapman discussed the advantages and high points of attending a conference like AAPS Bio, but also went into detail about some of the...
-
1 month ago | 
biopharminternational.com | Patrick Lavery
Pharmaceutical Technology® Group interfaced with nearly a dozen companies at the annual INTERPHEX conference in New York City on April 1 and 2, 2025, and while one of the overarching topics may have been the tariff policies of United States President Donald Trump’s administration—in which there were new developments during the event—many of the interviewees over those two days were eager to share their businesses’ latest innovations in manufacturing and how those might fit into the industry...
-
1 month ago | 
biopharminternational.com | Patrick Lavery
Biocon Biologics, a subsidiary of India-based Biocon, announced on May 25, 2025, that its biosimilar of ustekinumab, under the brand name Yesintek, was granted marketing approval by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) (1). The agent is indicated for the treatment of adults and children aged 6 and older who have moderate to severe plaque psoriasis, as well as adults with active psoriatic arthritis or moderately to severely active Crohn’s disease.
